AAAAAA

   
Results: 1-11 |
Results: 11
Thalidomide dose proportionality assessment following single doses to healthy subjects
Authors: Teo, SK Scheffler, MR Kook, KA Tracewell, WG Colburn, WA Stirling, DI Thomas, SD
Citation: Sk. Teo et al., Thalidomide dose proportionality assessment following single doses to healthy subjects, J CLIN PHAR, 41(6), 2001, pp. 662-667
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Authors: Atkinson, AJ Colburn, WA DeGruttola, VG DeMets, DL Downing, GJ Hoth, DF Oates, JA Peck, CC Schooley, RT Spilker, BA Woodcock, J Zeger, SL
Citation: Aj. Atkinson et al., Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework, CLIN PHARM, 69(3), 2001, pp. 89-95
Hemoglobin and methemoglobin concentrations after large-dose infusions of diaspirin cross-linked hemoglobin
Authors: O'Hara, JF Colburn, WA Tetzlaff, JE Novick, AC Angermeier, KW Schubert, A
Citation: Jf. O'Hara et al., Hemoglobin and methemoglobin concentrations after large-dose infusions of diaspirin cross-linked hemoglobin, ANESTH ANAL, 92(1), 2001, pp. 44-48
Single- and multiple-dose pharmacokinetics of ziprasidone in healthy youngand elderly volunteers
Authors: Wilner, KD Tensfeldt, TG Baris, B Smolarek, TA Turncliff, RZ Colburn, WA Hansen, RA
Citation: Kd. Wilner et al., Single- and multiple-dose pharmacokinetics of ziprasidone in healthy youngand elderly volunteers, BR J CL PH, 49, 2000, pp. 15S-20S
Effect of a high-fat meal on thalidomide pharmacokinetics and the relativebioavailability of oral formulations in healthy men and women
Authors: Teo, SK Scheffler, MR Kook, KA Tracewell, WG Colburn, WA Stirling, DI Thomas, SD
Citation: Sk. Teo et al., Effect of a high-fat meal on thalidomide pharmacokinetics and the relativebioavailability of oral formulations in healthy men and women, BIOPHARM DR, 21(1), 2000, pp. 33-40
An evolution of drug development and clinical pharmacology during the 20thcentury
Authors: Heath, G Colburn, WA
Citation: G. Heath et Wa. Colburn, An evolution of drug development and clinical pharmacology during the 20thcentury, J CLIN PHAR, 40(9), 2000, pp. 918-929
Bioavailability and bioequivalence: Average, population and/or individual
Authors: Colburn, WA Keefe, DL
Citation: Wa. Colburn et Dl. Keefe, Bioavailability and bioequivalence: Average, population and/or individual, J CLIN PHAR, 40(6), 2000, pp. 559-560
Pharmacokinetic/pharmacodynamic modeling in drug research and development
Authors: Derendorf, H Lesko, LJ Chaikin, P Colburn, WA Lee, P Miller, R Powell, R Rhodes, G Stanski, D Venitz, J
Citation: H. Derendorf et al., Pharmacokinetic/pharmacodynamic modeling in drug research and development, J CLIN PHAR, 40(12), 2000, pp. 1399-1418
Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development
Authors: Colburn, WA
Citation: Wa. Colburn, Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development, J CLIN PHAR, 40(12), 2000, pp. 1419-1427
Products approved for marketing during 1998
Authors: Colburn, WA
Citation: Wa. Colburn, Products approved for marketing during 1998, J CLIN PHAR, 39(5), 1999, pp. 439-441
Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers
Authors: Teo, SK Colburn, WA Thomas, SD
Citation: Sk. Teo et al., Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers, J CLIN PHAR, 39(11), 1999, pp. 1162-1168
Risultati: 1-11 |